Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
7 Subcutaneous semaglutide was approved in 2021 and 2022 as Wegovy for weight loss in patients 12 and older after the STEP1 trial showed patients who took subcutaneous semaglutide had a -14.9% body weight reduction (-15.3kg) compared to -2.4% (-2.6kg) with placebo after 68 weeks
GLP-1 drugs such as semaglutide and tirzepatide have helped millions of people combat Type 2 diabetes and cardiovascular (heart) disease, as well as shed weight
Primary storage Refrigerate at 2 to 8 degrees Celsius
doi:10.1291/hypres.28.223
US$ 24.90
US$ 27.06
US$ 27.73
US$ 29.75
US$ 19.99
US$ 22.78
US$ 24.43
